NeoGenomics - NEO Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NEO shares.
View NEO analyst ratings or view top-rated stocks.

12 analysts have issued twelve-month target prices for NeoGenomics' shares. Their NEO share price forecasts range from $12.00 to $30.00. On average, they predict the company's stock price to reach $18.92 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.

NeoGenomics' stock was trading at $9.24 at the beginning of 2023. Since then, NEO shares have increased by 37.3% and is now trading at $12.69.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NEO earnings forecast.

NeoGenomics, Inc. (NASDAQ:NEO) released its quarterly earnings data on Tuesday, November, 8th. The medical research company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.06. The medical research company earned $128.78 million during the quarter, compared to analysts' expectations of $122.55 million. NeoGenomics had a negative net margin of 32.88% and a negative trailing twelve-month return on equity of 9.46%.

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.21%), Perkins Capital Management Inc. (0.16%), Oak Family Advisors LLC (0.08%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.06%) and Nisa Investment Advisors LLC (0.04%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEO stock can currently be purchased for approximately $12.69.

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.60 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

The company employs 2,000 workers across the globe.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.